Results 271 to 280 of about 31,538 (351)
Central Nervous System Bleeding in Children With Haemophilia in Limited Resource
ABSTRACT Introduction Central nervous system (CNS) bleeding in children with haemophilia is a life‐threatening complication that may cause severe neurological sequelae or death. In resource‐limited settings, where prophylaxis is not universally accessible, its patterns and outcomes may differ from those in high‐income countries.
Patcharee Komvilaisak +5 more
wiley +1 more source
ABSTRACT Introduction The National Bleeding Disorder Foundation (NBDF) Medical and Scientific Advisory Council (MASAC) was formed in 1954 and issues recommendations and advisories pertinent to the bleeding disorders community. MASAC is comprised of > 25 rotating members from different medical disciplines and lived experience experts.
Glaivy Batsuli +15 more
wiley +1 more source
Use of andexanet alfa: A British Society for Haematology position statement
British Journal of Haematology, EarlyView.
Richard J. Buka +10 more
wiley +1 more source
FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita +2 more
wiley +1 more source
ABSTRACT Introduction Recent advances in prophylaxis with clotting factor concentrates have enabled people with haemophilia (PwH) to participate in high‐intensity exercises; however, this does not preclude them from sports‐induced bleeding (SIB). Aim To investigate factors influencing the recent occurrence of SIB among PwH.
Rie Shirayama +3 more
wiley +1 more source
Comparative efficacy of hemostatic agents in dermatologic surgery: A systematic review [PDF]
Isabella Ribaudo +7 more
openalex +1 more source
ABSTRACT Introduction The therapeutic landscape for patients with haemophilia A (PwHA) is rapidly evolving with the introduction of extended half‐life FVIII (EHL‐FVIII) and non‐FVIII therapies that mimic FVIII, such as emicizumab (EMI). Monitoring non‐factor therapies in the laboratory poses challenges; however, the thrombin generation assay (TGA) can ...
Jessica Garcia +4 more
wiley +1 more source
The use of topical hemostatic agents in spinal surgery
С. В. Колесов +11 more
openalex +1 more source

